Medicare Enrolled
Dr. Mahshid Mosallaei-Benjamin, M.D.
Medical Oncology · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mosallaei-Benjamin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mosallaei-Benjamin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mosallaei-Benjamin
Dr. Mahshid Mosallaei-Benjamin is a medical oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mosallaei-Benjamin performed 53,667 Medicare services across 2,196 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mosallaei-Benjamin received a total of $211 from 5 pharmaceutical and/or device companies across 6 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mosallaei-Benjamin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 8% volume in CA
$211 industry payments
Medicare Practice Summary
Medicare Utilization ↗53,667
Medicare services
Top 8% in CA for medical oncology
2,196
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,825 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
10,710 | $0 | $10 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
10,050 | $0 | $10 |
| Denosumab injection (Prolia/Xgeva) | 8,400 | $19 | $94 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 6,450 | $38 | $172 |
| Injection, docetaxel, 1 mg | 4,987 | $0 | $72 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
1,620 | $26 | $335 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,520 | $1 | $95 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,392 | $0 | $5 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
810 | $8 | $58 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
646 | $1 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
640 | $104 | $857 |
| Injection, leucovorin calcium, per 50 mg | 632 | $3 | $20 |
| Anti-nausea injection (ondansetron/Zofran) | 620 | $0 | $11 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
585 | $14 | $245 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
468 | $86 | $1,587 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
418 | $2 | $257 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
405 | $2 | $16 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
398 | $8 | $25 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
352 | $120 | $1,071 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
328 | $149 | $960 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
276 | $12 | $122 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
255 | $57 | $386 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
229 | $7 | $487 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
172 | $26 | $550 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
158 | $1 | $10 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
156 | $18 | $150 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
127 | $59 | $620 |
| New patient office visit, complex (60-74 min) | 120 | $179 | $1,360 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
103 | $27 | $475 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
103 | $71 | $508 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
80 | $30 | $270 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
73 | $1 | $15 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 65 | $134 | $4,038 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
63 | $51 | $452 |
| 5% dextrose/water (500 ml = 1 unit) | 58 | $1 | $15 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
53 | $23 | $185 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
44 | $2 | $25 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
43 | $121 | $1,174 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
32 | $27 | $155 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
26 | $18 | $98 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
26.3% high complexity
68.8% medium
4.9% routine
Industry Payment Transparency
Open Payments through 2022 ↗$211
Total received (2018-2022)
Avg $70/year across 3 years
Bottom 16% in CA for medical oncology
5
Companies
6
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$185 (87.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$26 (12.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2022
$15
2019
$36
2018
$160
Payments by company (2022)
Consulting
Speaking
Meals & Travel
Research
Myriad Genetic Laboratories, Inc.
$15
Top 3 companies account for 100.0% of 2022 payments
All-time payments by company (2018-2022) ›
Genentech USA, Inc.
$145
PFIZER INC.
$26
Myriad Genetic Laboratories, Inc.
$15
TESARO, Inc.
$12
Takeda Pharmaceuticals U.S.A., Inc.
$12
Top 3 companies account for 88.3% of all-time payments
Associated products mentioned in payments ›
BAVENCIO · NINLARO · TALZENNA · VENCLEXTA · ZEJULA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
44
Per 100K population
0.4
County median income
$87,760
Nearest hospital
RONALD REAGAN UCLA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2022 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mosallaei-Benjamin is a mixed practice specialist, with above-average Medicare volume (top 8% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mosallaei-Benjamin experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Mosallaei-Benjamin performed 10,710 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mosallaei-Benjamin receive payments from pharmaceutical companies?
Yes. Dr. Mosallaei-Benjamin received a total of $211 from 5 companies across 6 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mosallaei-Benjamin's costs compare to other medical oncologists in Los Angeles?
Dr. Mosallaei-Benjamin's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mosallaei-Benjamin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Los Angeles
Browse medical oncologists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology